Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Public ClinicalTrials.gov record NCT00122317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
Study identification
- NCT ID
- NCT00122317
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2005 (Actual)
- Primary completion
- Sep 2008 (Actual)
- Completion
- Oct 2008 (Actual)
- Last update posted
- Mar 13, 2018
2005 – 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Medical Center, Division of Hematology | Stanford | California | 94305 | — |
| Hartford Hospital, Cancer Clinical Research Office | Hartford | Connecticut | 06102 | — |
| Cleveland Clinic Florida, Department of Clinical Research | Weston | Florida | 33331 | — |
| Indianapolis University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Johns Hopkins University Medical Center | Baltimore | Maryland | 21205 | — |
| National Heart, Lung, and Blood Institute, National Institutes of Health | Bethesda | Maryland | 20892 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic, Divison of Hematology | Rochester | Minnesota | 55902 | — |
| Washington University, Department of Internal Medicine/Division of Hematology | St Louis | Missouri | 63110 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10017 | — |
| Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00122317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 13, 2018 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00122317 live on ClinicalTrials.gov.